Sign in Subscribe

retrospective

A collection of 92 issues

Machine learning models tested for mortality prediction in Tennessee early-onset CRC patients

Skip to content The CRC Digest Machine learning models tested for mortality prediction in Tennessee early-onset CRC patients A retrospective study of 3,467 Tennessee patients aged 20–49 compared machine learning algorithms for predicting all-cause mortality and 1-, 3-, and 5-year mortality. (Cancer Epidemiol) This content is informational only

Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapy

Skip to content The CRC Digest ◇ RESEARCH Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapy A retrospective cohort study of 221 metastatic CRC patients receiving anti-PD-1/PD-L1 immunotherapy plus chemotherapy assessed tumor mutational burden as a biomarker for survival and quality of life outcomes. (Medicine) This

Study assesses impact of concurrent palliative care on metastatic CRC patients on systemic therapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study assesses impact of concurrent palliative care on metastatic CRC patients on systemic therapy A retrospective study of 201 metastatic CRC patients assessed the impact of concurrent multidisciplinary palliative care alongside systemic therapy on patient-reported outcomes and healthcare utilization. (Front Oncol)

Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases

Skip to content The CRC Digest Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC Database evaluated the prognostic impact of liver metastases and KRAS mutations in metastatic colorectal cancer patients. (Clinical Colorectal Cancer) This content is

Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib combined with panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only

Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes

Skip to content The CRC Digest Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated

39-year-old proband with Lynch syndrome shows discordant tumor testing

Skip to content The CRC Digest ◇ RESEARCH 39-year-old proband with Lynch syndrome shows discordant tumor testing A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)

Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining

Skip to content The CRC Digest ◇ RESEARCH Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining A family carrying germline MLH1 c.931A>G presented with colorectal tumors showing retained mismatch repair protein expression by immunohistochemistry but microsatellite instability-high status on sequencing, highlighting that preserved staining does

Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles

Skip to content The CRC Digest ◇ RESEARCH Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles Researchers report a rare collision tumor composed of two adjacent primary colorectal carcinomas, one harboring a TPR::NTRK fusion with MSI-H and high tumor mutational burden, the other showing conventional adenocarcinoma

Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases

Skip to content The CRC Digest ▸ TREATMENT Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Retrospective study (2009–2024) evaluated cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases. (Radiol Oncol) This content is informational only and does not constitute medical advice. Always